title: [Study on the therapy of castration-resistant prostate cancer : Randomized phase II study of abiraterone acetate with LHRH therapy vs. abiraterone acetate without LHRH therapy in patients with progressive chemotherapy-naive castration-resistant prostate cancer (SPARE) - AP 67/11 of the Association of Urogenital Oncology (AUO)].
authors.affiliation: AUO-Geschäftsstelle, MeckEvidence, Seestr. 11, 17252, Schwarz, Deutschland. auo.presse@MeckEvidence.de.
authors.forename: H
authors.initials: H
authors.lastname: Rexer
mesh_terms: D000069501:Abiraterone Acetate / Q000627:therapeutic use*; D018450:Disease Progression; D018572:Disease-Free Survival; D004359:Drug Therapy, Combination; D005858:Germany; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy*
chemical_list: D007987:Gonadotropin-Releasing Hormone; D000069501:Abiraterone Acetate